| Michael Porter |
Michael Porter is currently the President, Chief Executive Officer & Director at AMAG Pharma USA, Inc., as well as the Chief Executive Officer at Covis Pharma Holdings BV, Covis Pharma US, Inc., and President & Director at AMAG Pharmaceuticals, Inc. Previously, he was the Chief Operating & Financial Officer at Covis Pharma Holdings SARL. He holds an MBA from Columbia Business School. |
| Anne M. Phillips |
Dr. Anne M. Phillips, MD, is an Independent Director at vTv Therapeutics, Inc., an Independent Director at Carmot Therapeutics, Inc., an Independent Non-Executive Director at Barinthus Biotherapeutics Plc, an Independent Director at Vaccitech (UK) Ltd., an Independent Director at Trevena, Inc. and a Fellow at Royal College of Physicians & Surgeons of Canada. She is on the Board of Directors at vTv Therapeutics, Inc., Carmot Therapeutics, Inc., Barinthus Biotherapeutics Plc, Vaccitech (UK) Ltd., Trevena, Inc. and AMAG Pharmaceuticals, Inc. Dr. Phillips was previously employed as an Independent Director by AMAG Pharmaceuticals, Inc., a Senior VP-Clinical, Medical & Regulatory Affairs by Novo Nordisk, Inc., a Vice President-Medicine Development by GlaxoSmithKline LLC, a Head-Infectious Diseases Program by St. Michael's Hospital, and a Chief-Infectious Diseases & Associate Professor by Wellesley Hospital. She also served on the board at Biotechnology Innovation Organization. She received her undergraduate degree from the University of Western Ontario and a doctorate degree from the University of Toronto. |
